Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Associate

Della Fok

Goodwin Procter

main

Fok Della

Goodwin Associate Della Fok, from New York, in Goodwin’s Business Law Department and a member of its Life Sciences group

Della Fok

Areas of Practice

Professional Experience

Credentials

Education

JD2016

BA2011

Admissions

Bars

Related Content

EQRx’s Acquisition by Revolution Medicines is Complete

Goodwin Represents the Initial Purchasers and Dealers on Enovis Corporation’s $460 million 3.875% Convertible Senior Notes Offering and Capped Call

Goodwin Israel Practice Advises on Five M&A Transactions, a Registered Direct Offering, and Multiple Financings

EQRx To Be Acquired By Revolution Medicines In All-Stock Transaction

Brainstorm Cell Therapeutics Closes $7.5 Million Registered Direct Offering

TransCode Therapeutics Closes $7 Million Public Offering

GreenLight Biosciences to be Acquired in a Go-Private Transaction by a Consortium Led by Fall Line Endurance Fund

Fulcrum Therapeutics Closes $125 Million Public Offering of Common Stock

Life Sciences